Embattled pathology group Healius has stepped up internal restructuring and cost-cutting in a push to lift its financial performance as investment bankers UBS oversee a strategic review.
Two top executives in the group’s Queensland pathology business QML have departed in the restructure outlined in an internal email on March 27 from the boss of the Healius Pathology division, Jan Van Rooyen.
Loading...
Simon Evans writes on business specialising in retail, manufacturing, beverages, mining and M&A. He is based in Adelaide. Connect with Simon on Twitter. Email Simon at simon.evans@afr.com
